ORIC reported Q4 2025 net loss of USD 30.51 million and R&D expenses of USD 25.86 million, while G&A expenses were USD 8.7 million. For FY 2025, ORIC posted a net loss of USD 129.47 million on R&D expenses of USD 109.82 million and G&A expenses of USD 33.19 million. Cash, cash equivalents and investments totaled USD 392.3 million as of Dec. 31, 2025, and ORIC said that after raising an additional USD 20 million under its ATM program subsequent to year-end, pro forma cash and investments were USD 412.3 million, which it expects to fund its operating plan into 2H 2028. On the business side, ORIC highlighted Phase 1b dose exploration data for rinzimetostat in metastatic castration-resistant prostate cancer, including PSA50 responses in 55% of patients (11/20) and PSA90 responses in 20% (4/20), and said it selected provisional recommended Phase 2 doses for combination with darolutamide and apalutamide. The company also presented Phase 1b data for enozertinib in NSCLC with EGFR exon 20 and EGFR PACC mutations, including preliminary 1L systemic ORR of 67% (EGFR exon 20) and 80% (EGFR PACC), and 100% intracranial ORR in both groups among patients with measurable CNS disease. ORIC said it raised USD 264 million from healthcare specialist funds and expects multiple clinical readouts for rinzimetostat and enozertinib in 2026, including rinzimetostat combination dose optimization data in 1Q 2026 and initiation of its first global Phase 3 registrational trial in mCRPC in 1H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9659497-en) on February 23, 2026, and is solely responsible for the information contained therein.